Japan Approves CSL and Arcturus Therapeutics' Updated mRNA COVID-19 Vaccine for JN.1 Strain, Distributed by Meiji Seika Pharma

Sep 13, 2024, 12:04 PM

Japan's Ministry of Health, Labor and Welfare has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA COVID-19 vaccine for protection against the JN.1 strain. The vaccine will be distributed in Japan by Meiji Seika Pharma. This approval marks a significant step in Japan's efforts to combat the ongoing pandemic, leveraging advanced mRNA technology to enhance immunity against emerging strains. CSL and Meiji Seika Pharma are key players in this initiative.